– USA, IA – NewLink Genetics Corporation (NASDAQ:NLNK), today announced the appointment of Chad A. Johnson to the Company’s Board of Directors. In connection with this appointment, the Company’s Board expanded from seven directors to eight.
“We welcome Mr. Johnson to our Board of Directors,” said Charles J. Link, Jr, MD, Chairman and Chief Executive Officer. “His experience as a corporate officer, including governance, legal, and strategic business issues are important additions to NewLink Genetics.”
Mr. Johnson is currently Vice President, General Counsel for the Stine Seed Company, the world’s largest private seed company. In that role, Chad is responsible for managing all legal issues of concern to the company.
Prior to his position with Stine Seed Company, Chad was the Assistant Corporate Secretary and Senior Corporate Counsel for Renewable Energy Group, Inc., the largest supplier of advanced biofuels by volume in North America. In addition to his role as a corporate officer, Chad was a senior in-house attorney for the company where he helped advance the company’s strategic expansion into Europe and other merger and acquisition activities, managed the company’s intellectual property portfolio and managed the legal aspects of the company’s securities and public filings. Before joining Renewable Energy Group, Chad spent eight years in roles of increasing responsibility at DuPont Pioneer, a subsidiary of DuPont and a global leading seed and agriculture biotechnology company. In those roles, he provided legal guidance to a variety of businesses in connection with mergers and acquisitions, strategic collaborations with industry partners and compliance initiatives. Chad is admitted to practice law in the state of Iowa and before the United States Patent and Trademark Office.
Mr. Johnson graduated from Iowa State University with a Master of Science in Crop Production and Physiology and received his J.D. from Drake University Law School.
“It’s an exciting time to be joining NewLink Genetics,” said Mr. Johnson. “I look forward to working with the Board and the management team as the company advances toward multiple data disclosures from its clinical programs in cancer indications.”
About NewLink Genetics Corporation
NewLink Genetics is a late-stage biopharmaceutical company focusing on discovering, developing and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer. NewLink Genetics’ IDO pathway inhibitors are designed to harness multiple components of the immune system to combat cancer.
For more information : http://www.newlinkgenetics.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
Comments are closed.